Cite

HARVARD Citation

    Li, Z. et al. (n.d.). Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clinical and experimental immunology. pp. 295-314. [Online]. 
  
Back to record